These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 35027753)

  • 1. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
    Theruvath J; Menard M; Smith BAH; Linde MH; Coles GL; Dalton GN; Wu W; Kiru L; Delaidelli A; Sotillo E; Silberstein JL; Geraghty AC; Banuelos A; Radosevich MT; Dhingra S; Heitzeneder S; Tousley A; Lattin J; Xu P; Huang J; Nasholm N; He A; Kuo TC; Sangalang ERB; Pons J; Barkal A; Brewer RE; Marjon KD; Vilches-Moure JG; Marshall PL; Fernandes R; Monje M; Cochran JR; Sorensen PH; Daldrup-Link HE; Weissman IL; Sage J; Majeti R; Bertozzi CR; Weiss WA; Mackall CL; Majzner RG
    Nat Med; 2022 Feb; 28(2):333-344. PubMed ID: 35027753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
    Anderson KL; Snyder KM; Ito D; Lins DC; Mills LJ; Weiskopf K; Ring NG; Ring AM; Shimizu Y; Mescher MF; Weissman IL; Modiano JF
    Melanoma Res; 2020 Apr; 30(2):147-158. PubMed ID: 31205227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma.
    Tang XX; Shimada H; Ikegaki N
    Curr Oncol; 2024 Jun; 31(6):3212-3226. PubMed ID: 38920727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on.
    Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE
    Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
    Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
    Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.
    Luo W; Hoang H; Miller KE; Zhu H; Xu S; Mo X; Garfinkle EAR; Costello H; Wijeratne S; Chemnitz W; Gandhi R; Liao Y; Ayello J; Gardenswartz A; Rosenblum JM; Cassady KA; Mardis ER; Lee DA; Cripe TP; Cairo MS
    J Exp Clin Cancer Res; 2024 Jul; 43(1):193. PubMed ID: 38992659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
    Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
    J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
    Votava M; Bartolini R; Capkova L; Smetanova J; Jiri V; Kuchar M; Kalfert D; Plzak J; Bartunkova J; Strizova Z
    BMC Cancer; 2022 Sep; 22(1):1021. PubMed ID: 36171566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
    Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
    ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.
    Zhuang Z; Zhou J; Qiu M; Li J; Lin Z; Yi H; Liu X; Huang C; Tang B; Liu B; Li X
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade.
    Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
    Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
    Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
    [No Abstract]   [Full Text] [Related]  

  • 18. CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis.
    Morrissey MA; Kern N; Vale RD
    Immunity; 2020 Aug; 53(2):290-302.e6. PubMed ID: 32768386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
    Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
    Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
    Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.